275 related articles for article (PubMed ID: 33150526)
1. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
Mahmood I
Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
[TBL] [Abstract][Full Text] [Related]
3. PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.
Hsueh CH; Hsu V; Zhao P; Zhang L; Giacomini KM; Huang SM
Clin Pharmacol Ther; 2018 Mar; 103(3):485-492. PubMed ID: 28738449
[TBL] [Abstract][Full Text] [Related]
4. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents.
Mahmood I; Tegenge MA
J Clin Pharmacol; 2019 Feb; 59(2):189-197. PubMed ID: 30192373
[TBL] [Abstract][Full Text] [Related]
5. Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.
Scotcher D; Jones CR; Galetin A; Rostami-Hodjegan A
J Pharmacol Exp Ther; 2017 Mar; 360(3):484-495. PubMed ID: 28057840
[TBL] [Abstract][Full Text] [Related]
6. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy.
Xia B; Heimbach T; Gollen R; Nanavati C; He H
AAPS J; 2013 Oct; 15(4):1012-24. PubMed ID: 23835676
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population.
Yee KL; Li M; Cabalu T; Sahasrabudhe V; Lin J; Zhao P; Jadhav P
J Clin Pharmacol; 2018 Mar; 58(3):364-376. PubMed ID: 29077203
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
Lasseter KC; Sologuren A; La Noce A; Dilzer SC
Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
[TBL] [Abstract][Full Text] [Related]
9. Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
Zhou J; You X; Guo G; Ke M; Xu J; Ye L; Wu W; Huang P; Lin C
J Clin Pharmacol; 2021 Dec; 61(12):1646-1656. PubMed ID: 34329494
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients.
Cui C; Li X; Liang H; Hou Z; Tu S; Dong Z; Yao X; Zhang M; Zhang X; Li H; Zuo X; Liu D
Biopharm Drug Dispos; 2021 Jan; 42(1):24-34. PubMed ID: 33340419
[TBL] [Abstract][Full Text] [Related]
11. Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example with Lamivudine.
Shah K; Fischetti B; Cha A; Taft DR
Curr Drug Discov Technol; 2020; 17(3):387-396. PubMed ID: 30767745
[TBL] [Abstract][Full Text] [Related]
12. Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
You X; Wu W; Xu J; Jiao Z; Ke M; Huang P; Lin C
J Clin Pharmacol; 2020 Aug; 60(8):999-1010. PubMed ID: 32090332
[TBL] [Abstract][Full Text] [Related]
13. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.
Wu W; Ke M; Ye L; Lin C
Eur J Clin Pharmacol; 2021 Jul; 77(7):989-998. PubMed ID: 33447912
[TBL] [Abstract][Full Text] [Related]
14. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
[TBL] [Abstract][Full Text] [Related]
15. Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children.
Zhou W; Johnson TN; Xu H; Cheung S; Bui KH; Li J; Al-Huniti N; Zhou D
CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):475-83. PubMed ID: 27566992
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.
De Sousa Mendes M; Hirt D; Urien S; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Benaboud S
Br J Clin Pharmacol; 2015 Nov; 80(5):1031-41. PubMed ID: 26011128
[TBL] [Abstract][Full Text] [Related]
17. Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption.
Huang W; Isoherranen N
CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):571-583. PubMed ID: 32977369
[TBL] [Abstract][Full Text] [Related]
18. Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.
Horiuchi K; Ohnishi S; Matsuzaki T; Funaki S; Watanabe A; Mizutare T; Matsumoto S; Nezasa KI; Hasegawa H
J Pharm Sci; 2018 May; 107(5):1443-1453. PubMed ID: 29331382
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
Czock D; Keller F; Seidling HM
Br J Clin Pharmacol; 2012 Jul; 74(1):66-74. PubMed ID: 22242561
[TBL] [Abstract][Full Text] [Related]
20. The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties.
Cristea S; Krekels EHJ; Allegaert K; Knibbe CAJ
Clin Pharmacokinet; 2020 Oct; 59(10):1291-1301. PubMed ID: 32314184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
